Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

343 ARTÍCULOS , VIENDO DEL 31 AL 45

Effect of TTP488 in patients with mild to moderate Alzheimer's disease

Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM.

BMC Neurol. 2014 Jan 15;14:12. doi: 10.1186/1471-2377-14-12.

Early psychosocial intervention in Alzheimer's disease: cost utility evaluation alongside the Danish Alzheimer's Intervention Study (DAISY)

Søgaard R, Sørensen J, Waldorff FB, Eckermann A, Buss DV, Phung KT, Waldemar G; DAISY Study Investigators.

BMJ Open. 2014 Jan 15;4(1):e004105. doi: 10.1136/bmjopen-2013-004105.

The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area

Araki T, Wake R, Miyaoka T, Kawakami K, Nagahama M, Furuya M, Limoa E, Liaury K, Hashioka S, Murotani K, Horiguchi J.

Int J Geriatr Psychiatry. 2014 Sep;29(9):881-9. doi: 10.1002/gps.4074. Epub 2014 Jan 17.

Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?

Panza F, Logroscino G, Imbimbo BP, Solfrizzi V.

Curr Opin Psychiatry. 2014 Mar;27(2):128-37. doi: 10.1097/YCO.0000000000000041.

Understanding the relative importance of preserving functional abilities in Alzheimer's disease in the United States and Germany

Hauber AB, Mohamed AF, Johnson FR, Cook M, Arrighi HM, Zhang J, Grundman M.

Qual Life Res. 2014 Aug;23(6):1813-21. doi: 10.1007/s11136-013-0620-5. Epub 2014 Jan 22.

Antiamyloid therapy for Alzheimer's disease--are we on the right road?

Karran E, Hardy J.

N Engl J Med. 2014 Jan 23;370(4):377-8. doi: 10.1056/NEJMe1313943.

A brief report on the efficacy of donepezil in pain management in Alzheimer's disease

Gharaei H, Shadlou H.

J Pain Palliat Care Pharmacother. 2014 Mar;28(1):37-9. doi: 10.3109/15360288.2013.876484. Epub 2014 Jan 23.

Galantamine treatment in outpatients with mild Alzheimer's disease

Richarz U, Gaudig M, Rettig K, Schauble B.

Acta Neurol Scand. 2014 Jun;129(6):382-92. doi: 10.1111/ane.12195. Epub 2014 Jan 25.

From the editor

Garner JD.

J Women Aging. 2014;26(1):1-2. doi: 10.1080/08952841.2013.815562.

Phytoestrogens and cognitive function: a review

Soni M, Rahardjo TB, Soekardi R, Sulistyowati Y, Lestariningsih, Yesufu-Udechuku A, Irsan A, Hogervorst E.

Maturitas. 2014 Mar;77(3):209-20. doi: 10.1016/j.maturitas.2013.12.010. Epub 2014 Jan 8.

Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?

Fischer A.

Neuropharmacology. 2014 May;80:95-102. doi: 10.1016/j.neuropharm.2014.01.038. Epub 2014 Jan 31.

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G.

Expert Rev Clin Immunol. 2014 Mar;10(3):405-19. doi: 10.1586/1744666X.2014.883921. Epub 2014 Feb 4.

Parallel improvement of cognitive functions and P300 latency following donepezil treatment in patients with Alzheimer's disease: a case-control study

Chang YS, Chen HL, Hsu CY, Tang SH, Liu CK.

J Clin Neurophysiol. 2014 Feb;31(1):81-5. doi: 10.1097/01.wnp.0000436899.48243.5e.

Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces

Rosini M, Simoni E, Minarini A, Melchiorre C.

Neurochem Res. 2014 Oct;39(10):1914-23. doi: 10.1007/s11064-014-1250-1. Epub 2014 Feb 4.

Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease

O'Caoimh R, Healy L, Gao Y, Svendrovski A, Kerins DM, Eustace J, Kehoe PG, Guyatt G, Molloy DW.

J Alzheimers Dis. 2014;40(3):595-603. doi: 10.3233/JAD-131694.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias